+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Healthcare Licensing - Non-Listed on Stock Exchanges Trends: Pharmaceuticals (Privately-owned Companies) Mid-Year Review

  • ID: 4604817
  • Report
  • July 2018
  • Region: Global
  • 175 pages
  • FinGlobe, Inc
1 of 2
This mid-year review report brings at one place all licensing deals and negotiations that took place between the privately-owned pharmaceuticals companies of Japan, US and Europe during January 1, 2018 to June 30, 2018. Further, the licensing deals and negotiations that took place between the privately-owned pharmaceuticals companies of other select regions and Japan, US and Europe during this period are also studied and included here. Also, the licensing deals and negotiations that took place within the privately-owned pharmaceuticals companies of Japan, US and Europe as well as within the privately-owned pharmaceuticals companies of countries/regions other than Japan, US and Europe are studied and included here. Moreover, all this collected data is comprehensively analyzed to understand the licensing trends and directions among the privately-owned companies during this time period.

Key Features:
  • 6 months’ Japan-US-Europe licensing transactions of privately-owned pharmaceuticals companies at one place
  • 6 months’ other select regions licensing transactions of privately-owned pharmaceuticals companies at one place
  • Curated categorizations of licensing details
  • 8+ variables reflecting different forms of transactions done
  • Canada/Australia/NZ licensing trends of privately-owned pharmaceuticals companies with Japan-US-Europe covered
  • Emerging markets licensing trends of privately-owned pharmaceuticals companies with Japan-US-Europe covered
  • Licensing trends of privately-owned pharmaceuticals companies within Japan, US, Europe; and also within other select regions covered
  • Licensing trends and directions of privately-owned pharmaceuticals companies summarized
The Report is useful to:
  • Japan, US and Europe privately-owned pharmaceuticals companies planning to introduce products in each other’s markets
  • Privately-owned pharmaceuticals companies of select other regions planning to introduce products in Japan, US and European markets
  • Select other regions’ privately-owned pharmaceuticals companies planning to introduce products in each other’s markets
  • Privately-owned pharmaceuticals companies active in R&D and seeking new market base
  • Privately-owned pharmaceuticals company executives negotiating licensing deals
  • Investors analyzing varied kinds of transaction options for licensing deals of privately-owned pharmaceuticals companies
Key analysis provided: January-June 2018
  • Total number of licensing deals of privately-owned pharmaceuticals companies signed
  • Total number of privately-owned pharmaceuticals companies involved in licensing deals
  • Most licensing deals signed by which country’s privately-owned pharmaceuticals companies
  • Number of inbound and outbound licensing deals of privately-owned pharmaceuticals companies
  • Most licensing deals signed by which medicine groups
  • Licensing payment arrangements most followed in the global licensing deals of privately-owned pharmaceuticals companies
  • Number of domestic and worldwide licensing for privately-owned pharmaceuticals companies
  • Number of R&D and commercialization licensing for privately-owned pharmaceuticals companies
  • Number of licensing deals discontinued for privately-owned pharmaceuticals companies
Note: Product cover images may vary from those shown
2 of 2
Introduction

Research Design

Section 1: Inventions licensed between Privately-owned Pharmaceuticals companies of Japan and United States
1.1 By Japanese company name
1.2 By US company name
1.3 By Terms of payment
1.4 By Medical groups

Section 2: Inventions licensed between Privately-owned Pharmaceuticals companies of Japan and Europe
2.1 By Japanese company name
2.2 By Europe company name
2.3 By Terms of payment
2.4 By Medical groups

Section 3: Inventions licensed between Privately-owned Pharmaceuticals companies of United States and Europe
3.1 By US company name
3.2 By Europe company name
3.3 By Terms of payment
3.4 By Medical groups

Section 4: Inventions licensed between Privately-owned Pharmaceuticals companies of Japan-US-Europe and other select regions
4.1 Canada/Asia/Australia/NZ licensing news with Japan-US-Europe
4.2 Emerging markets licensing news with Japan-US-Europe
4.3 Undisclosed companies’ licensing news with Japan-US-Europe

Section 5: Inventions licensed within Privately-owned Pharmaceuticals companies of Japan, United States and Europe
5.1 Japan-Japan licensing news
5.2 US-US licensing news
5.3 Europe-Europe licensing news

Section 6: Inventions licensed among Privately-owned Pharmaceuticals companies of countries/regions other than Japan-US-Europe

Section 7: Trends in Japan-US-Europe and other select regions’ licensing deals of Privately-owned Pharmaceuticals companies
7.1 Countries with most licensing deals
7.2 Healthcare companies most active in outbound and inbound licensing deals
7.3 Medical groups most active in licensing
7.4 Licensing payment arrangements most followed
7.5 Worldwide licensing vs domestic licensing
7.6 R&D licensing vs commercialization licensing
7.7 Licensing deals which discontinued

Section 8: Trends and strategic directions

Appendices
Appendix 1 List of Japan-based privately-owned pharmaceuticals companies covered in this report
Appendix 2 List of US-based privately-owned pharmaceuticals companies covered in this report
Appendix 3 List of Europe-based privately-owned pharmaceuticals companies covered in this report
Appendix 4 List of other select regions’ privately-owned pharmaceuticals companies covered in this report
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll